On April 1st, the "China Brain Computer Interface Commercialization Outlook Report" was released, with a total financing amount of 2 billion yuan for QiangBrain Technology, 500 million yuan for Ladder Medical, and 300 million yuan for Zhiran Medical. The report statistics show that the total financing amount of China's brain computer interface enterprises in the first three months of this year exceeded that of the whole year of 2025, and the total financing amount is estimated to have exceeded 4 billion yuan. The clinical application of invasive brain computer interfaces has entered the "quasi commercialization" stage. What are the key steps for brain computer interface technology to break through bottlenecks and move towards widespread application? For this purpose, the reporter interviewed frontline experts. Clinical validation is a key link in the transition from laboratory to application, and it has become a consensus among brain computer interface developers. During this period, we have been in contact with over 100 brain computer interface projects with our dedicated neuroscience fund team, "Yang Xun, the investment project leader of the Investment Management Department of Sanbo Brain Hospital Management Group, told Science and Technology Daily reporters. Most companies are in the early stages of research and development and animal experiment verification. Yang Xun stated that taking the current focus of many brain computer interface technology companies on motor function rehabilitation, visual function rehabilitation, cognitive function rehabilitation, etc. as examples, the ability to obtain animal experiments for verification to some extent demonstrates the team's technical strength in neural signal decoding, but it does not mean that the data and algorithms from these animal experiments can be applied to humans, and further experimental verification is needed. Whether brain computer interface technology can be applied depends on the understanding of the human nervous system. Especially in terms of cognition, which is a human exclusive advanced function, animal experiments can only prove the safety of the product, and it is difficult to prove its effectiveness. Yang Xun stated that the brain computer interface project's transition from the laboratory concept validation stage to widespread application is a process that requires long-term effort and high-level research. Therefore, conducting clinical trials on humans as soon as possible plays a crucial role in the maturity of brain computer interface products. In the clinical treatment of related diseases, it also depends on the causes of the disease and the patient's physical tolerance. Enterprises need to cooperate with medical institutions in the research and development stage to promote the integration of engineering technology and clinical practice, in order to promote the rapid and healthy development of the brain computer interface industry. Yang Xun said that the current cooperative development ecology in China is taking shape, and many top hospitals are helping the industry development through medical translation centers and other institutions. Sanbo Brain Science has also built a clinical trial platform and selected projects for cooperation. Currently, many brain computer interface technology companies are focusing on the rehabilitation of motor functions such as treating paraplegic patients, and it is expected that some products may make breakthroughs in the future. ”Yang Xun said. The upgrading of materials will be one of the core breakthroughs in future products. Due to factors such as the physical properties of electrical conduction in the nervous system and the rejection response of the human immune system, the biocompatibility and safety of implant materials are of utmost concern in the industry. Invasive brain computer interface products require a portion of electrodes to be implanted into the skull or central nervous system, which is a complex neurosurgical procedure. Due to the non renewable nature of the central nervous system, any mistake can cause permanent damage. Yang Xun believes that even if the product obtains a medical device certificate in clinical practice, doctors and patients will be very cautious in implementation. The success of a project depends on many factors, and price is an unavoidable and important factor. ”Yang Xun summarized that invasive brain computer interface technology involves clinical medicine, materials science, chips AI、 Electronic engineering and other medical engineering interdisciplinary sciences have long clinical trial verification cycles, high initial R&D investment, and relatively complex clinical surgeries. The market will only experience rapid growth when product prices are lowered and affordable for ordinary patients. In addition to sufficient funding, the implementation of brain computer interface technology also requires leveraging the incubation capabilities of professional platforms. Yang Xun said that when encountering high-quality projects, Sanbo Brain Science will match the R&D team with a professional team of doctors after screening, and work together with them to accelerate product development. Yang Xun stated that the current investment boom can be seen as a necessary path for the development of emerging industries. Government departments and industry sectors can be guided by a good investment and financing ecosystem, prioritizing the transformation of brain computer interface technologies with solid experimental foundations from concepts to reality, supporting capital to enter the fast lane of high-tech incubation, and forming a driving engine for the development and application of brain computer interface technologies. (Looking into the New Era)